← Leaderboards
Joy A Phillips
Sidney Kimmel Cancer Center
$3,011,391
Attributed
$3,011,391
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $770.7K · FY2006–17$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$3,011,391 · 5
By mechanism
R21$1,817,820 · 4
R01$1,193,571 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseAgonistMediatingNeutrophilImmune ResponseVaccinationProgramsVaccinesEpitopesAge RelatedBinding (Molecular Function)AdjuvantCellsCytokineAgedPeptidesC5a Anaphylatoxin ReceptorAntigen-Presenting CellsExploratory/Developmental GrantImmunityInflammatoryBiologicalIn VivoCoupled
Grant awards (14)
Neonatal Antibiotic Therapy, The Pulmonary Microbiome, and theCholinergic Anti-inflammatory Pathway$225,375
R21 · FY2017 · AI · contact PI
Neonatal Antibiotic Therapy, The Pulmonary Microbiome, and theCholinergic Anti-inflammatory Pathway$187,500
R21 · FY2016 · AI · contact PI
Pulmonary delivery of a hybrid therapeutic to halt respiratory viral infection$297,333
R01 · FY2014 · GM · contact PI
Pulmonary delivery of a hybrid therapeutic to halt respiratory viral infection$287,370
R01 · FY2013 · GM · contact PI
Pulmonary delivery of a hybrid therapeutic to halt respiratory viral infection$297,817
R01 · FY2012 · GM · contact PI
Pulmonary delivery of a hybrid therapeutic to halt respiratory viral infection$311,051
R01 · FY2011 · GM · contact PI
Influenza A in the aged: a novel vaccination strategy$185,147
R21 · FY2008 · AI · contact PI
C5a Agonist as a Vaccine Adjuvant for the Aged$133,369
R21 · FY2008 · AG · contact PI
Influenza A in the aged: a novel vaccination strategy$45,400
R21 · FY2008 · AI · contact PI
C5a Agonist as a Vaccine Adjuvant for the Aged$29,054
R21 · FY2008 · AG · contact PI
Gene product delivery by engineered somatic cells$281,105
R21 · FY2007 · EB · contact PI
C5a Agonist as a Vaccine Adjuvant for the Aged$248,370
R21 · FY2007 · AG · contact PI
Influenza A in the aged: a novel vaccination strategy$241,250
R21 · FY2007 · AI · contact PI
Gene product delivery by engineered somatic cells$241,250
R21 · FY2006 · EB · contact PI